Cancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highlighting its promise and problems. Chapters in this release include The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy, Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy, Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?, Rational Design of adjuvants boosts cancer vaccines, Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma.

Other chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment.

• Discusses immune surveillance of tumors and how it is compromised
• Presents new approaches to the development and delivery of cancer vaccines and cytotoxic T-cells to the tumor site
• Demonstrates how new molecular biological approaches may augment the efficacy of CAR-T cells and dampen the effects of non-coding RNAs